SCHEMBL21473367

SCHEMBL21473367

CCOC(=O)C(CCC(=O)C=N)NC(=O)C(CC(C)C)NC(=O)C(N)CC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
NOD1 Q9Y239 2/20 0.36
PPID Q08752 1/20 0.36
CAPN9 O14815 1/20 0.35
CTSL P07711 2/20 0.35
LMNA P02545 1/20 0.35
CAPN1 P07384 1/20 0.35
CTSB P07858 1/20 0.35
CTSG P08311 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPY4R P50391 2/20 0.35
NPY1R P25929 1/20 0.35
BIRC2 Q13490 1/20 0.34
IL1RN P18510 1/20 0.34
ERAP2 Q6P179 1/20 0.34
PSMB5 P28074 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25760765 0.96 L3MBTL1 (0.42) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL18478760 0.88 L3MBTL1 (0.39) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL25760775 0.88 L3MBTL1 (0.37) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL20468543 0.85 L3MBTL1 (0.43) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL20465440 0.85 CTSL (0.39) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL18452352 0.85 CTSL (0.39) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL18476683 0.84 MME (0.34) NPY4RNPY1RBIRC2ERAP2
SCHEMBL26946628 0.84 MME (0.34) NPY4RNPY1RBIRC2ERAP2
SCHEMBL25760733 0.84 L3MBTL1 (0.42) L3MBTL1KMT2APOLBNOD1PPID
SCHEMBL20468545 0.84 L3MBTL1 (0.46) L3MBTL1KMT2APOLBNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) 2021-07-08 US disclosed
US-10738066-B2 Prodrugs of glutamine analogs THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-11 US disclosed
US-20190315784-A1 PRODRUGS OF GLUTAMINE ANALOGS DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206787-A1 PRODRUGS OF GLUTAMINE ANALOGS GLUL, GLS, GLS2 L3MBTL1 627/4885KMT2A 1913/4885POLB 2242/4885
US-10738066-B2 Prodrugs of glutamine analogs GLUL, GLS, GLS2 L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885
US-20190315784-A1 PRODRUGS OF GLUTAMINE ANALOGS GLUL, GLS, GLS2 L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.